Natural Capsules Ltd
Natural Capsules Q3 FY26: Revenue ₹37.75 Cr, EBITDA margin 6.16%
Q3 FY26 investor presentation: what the company reported on revenue, margins and projects.
Based on Natural Capsules Ltd's Q3 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q3FY26 revenue from operations: ₹37.75 crore - Year-on-year (Y-o-Y) revenue decline: 14% - Quarter-on-quarter (Q-o-Q) revenue decline: 18% - Capsules manufacturing capacity as of Q4FY25: 19.50 b Quarterly Financials (Q3FY26) - Revenue from Operations: ₹37.75 Cr (down 14% YoY) - EBITDA: ₹(2.33) Cr (down 155% YoY) - EBITDA Margin: (6.16%) (down 1,589 bps YoY) - Profit After Tax (PAT): ₹(7.12) Cr (down 6,833% YoY) - Explicit Margin Outlook - Management commentary (Page 7) notes stabilizing input costs and easing of US tariffs.
From Natural Capsules Ltd's Q3 FY26 earnings-call transcript · updated 16 Oct 2026.
Revenue & Sales Performance
- Q3FY26 revenue from operations: ₹37.75 crore
- Year-on-year (Y-o-Y) revenue decline: 14%
- Quarter-on-quarter (Q-o-Q) revenue decline: 18%
- Capsules manufacturing capacity as of Q4FY25: 19.50 billion capsules per annum (BCPA)
- Capacity utilization in FY25: 94.21%
- Management expects a meaningful improvement in Q4FY26 revenue as Puducherry regulatory issues have been resolved, and both plants are operational with demand normalizing (Page 7)
2 more points from Natural Capsules Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Natural Capsules Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Ongoing CAPEX to become market leader in capsules and dominate domestic steroidal API market (Page 31).
- Capsule capacity enhancement with state-of-the-art machinery for operational efficiency and profitability (Page 30).
- Exploring capsules manufacturing facilities in foreign/domestic markets for quick supply (Page 30).
- API facility approved by regulatory bodies under PLI scheme with planned capacities:
- Dexamethasone: 25 MT (imports ₹68 crores FY25), NCL only manufacturer in India (Page 22).
- Betamethasone: 44 MT (imports ₹179 crores FY25), NCL only manufacturer in India (Page 22).
- Prednisolone: 63 MT (imports ₹176 crores FY25), one of two manufacturers in India (Page 22).
- R&D investment to develop new products every 18 months and improve capsule machine output (Page 31).
2 more points from Natural Capsules Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Fundraising & Capital Structure
See what Natural Capsules Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Natural Capsules Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Natural Capsules Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹58 Cr, net loss ₹5 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Natural Capsules's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Wanbury (Q3 FY26)
Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against
- Gujarat Themis Biosyn Ltd (Q3 FY26)
43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q3 FY26)
Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2
- Ind-Swift Laboratories Ltd (Q3 FY26)
Q2 FY26 Revenue: ₹152.64 Cr (Total Income: ₹170.50 Cr), with a year-on-year (Y-o-Y) increase of 1.91%. Key investor presentation takeaways from Ind-Swift Labora
Arthneeti Pro · Annual
Natural Capsules Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Natural Capsules Ltd Q3 FY26 results?
Q3FY26 revenue from operations: ₹37.75 crore - Year-on-year (Y-o-Y) revenue decline: 14% - Quarter-on-quarter (Q-o-Q) revenue decline: 18% - Capsules manufacturing capacity as of Q4FY25: 19.50 b Quarterly Financials (Q3FY26) - Revenue from Operations: ₹37.75 Cr (down 14% YoY) - EBITDA: ₹(2.33) Cr (down 155% YoY) - EBITDA Margin: (6.16%) (down 1,589 bps YoY) - Profit After Tax (PAT): ₹(7.12) Cr (down 6,833% YoY) - Explicit Margin Outlook - Management commentary (Page 7) notes stabilizing input costs and easing of US tariffs.
What is Natural Capsules Ltd share price analysis?
Natural Capsules Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹167 Cr. Investors should review the full earnings analysis for detailed insights.
Is Natural Capsules Ltd planning capital expenditure?
Ongoing CAPEX to become market leader in capsules and dominate domestic steroidal API market (Page 31).
Keep Natural Capsules Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.